VSIG10: A Potential Drug Target and Biomarker (G54621)

Target Name: VSIG10

NCBI ID: G54621

VSIG10

Other Name(s): V-set and immunoglobulin domain-containing protein 10 | VSI10_HUMAN | V-set and immunoglobulin domain containing 10

VSIG10: A Potential Drug Target and Biomarker

VSIG10 is a protein that is expressed in various tissues of the body, including the liver, pancreas, and spleen. It is a member of the VSIG gene family, which includes several similar proteins that play a role in the immune response. VSIG10 has been shown to be involved in several biological processes, including inflammation, autoimmune diseases, and cancer. As a result, it has potential as a drug target or biomarker.

VSIG10 is a glycoprotein that consists of two heavy chains and two light chains. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region. VSIG10 is expressed in a variety of tissues, including the liver, pancreas, and spleen, and is also found in the bloodstream.

VSIG10 has been shown to be involved in several biological processes. One of its functions is to participate in the immune response by activating T cells. This is done through its engagement with the protein PD-1, which is aT cell receptor that is involved in cell survival and proliferation. VSIG10 is also involved in regulating inflammation, as is seen in the suppression of inflammation in response to VSIG10 deficiency.

VSIG10 has also been shown to be involved in the development and progression of certain types of cancer. For example, studies have shown that VSIG10 is often expressed in human cancer tissues and that its expression is associated with poor prognosis in patients with pancreatic cancer. Additionally, VSIG10 has been shown to be involved in the regulation of cell death, which is a critical process in cancer progression.

VSIG10 is a protein that has been shown to be involved in several important biological processes, including the immune response, inflammation, and cancer. As a result, it has potential as a drug target or biomarker. Researchers are currently working to identify small molecules that can interact with VSIG10 and determine its potential as a drug.

Protein Name: V-set And Immunoglobulin Domain Containing 10

The "VSIG10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VSIG10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets